Aug 13, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy ( RMAT ) designation for OPGx-LCA5 -
Aug 13, 2025 • Benzinga
NEUTRAL
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit - Perrigo ( NYSE:PRGO )
Perrigo restated over $1 billion in financial misstatements from 2015-2017. Shares plunged more than 62% after accounting and earnings disclosures. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →
Aug 13, 2025 • Zacks Commentary
NEUTRAL
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Aug 12, 2025 • Benzinga
NEUTRAL
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Aug 07, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.